This finding is consistent with the results of a patient preference survey of bolus insulin dose timing conducted in patients with T2DM that also used the MMAS-8 scale and reported poor adherence in approximately 24% of respondents [27]. The gene discussed is INS; the disease is type 2 diabetes mellitus.